tirzepatide discontinuation weight regain study Those discontinuing GLP-1 medications rapidly regained tirzepatide discontinuation GLP-1 receptor agonists

In summary, observational studies have not found an increased risk of PDAC during short term follow-up

February is heart month at Endocrine News , making it an opportune time to examine four recent studies that explore various aspects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and related incretin-based therapies, given obesitys profound impact on cardiovascular health

While the absolute risk remains lowestimated at 0.3% to 0.5% over 20 years of usefurther research is required to determine if similar risks exist for Wegovy, Ozempics counterpart for obesity treatment

GLP-1 tablets are effective for lowering A1C and supporting weight loss